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Abstract: 
 
The tumor suppressor gene RASSF1A is epigenetically silenced in most human cancers. 
As a binding partner of the kinases MST1 and MST2, the mammalian orthologues of the 
Drosophila Hippo kinase, RASSF1A is a potential regulator of the Hippo tumor 
suppressor pathway. RASSF1A shares these properties with the scaffold protein SAV1. 
The role of this pathway in human cancer has remained enigmatic inasmuch as Hippo 
pathway components are rarely mutated in tumors. Here we show that Rassf1a 
homozygous knockout mice develop liver tumors. However, heterozygous deletion of 
Sav1 or co-deletion of Rassf1a and Sav1 produced liver tumors with much higher 
efficiency than single deletion of Rassf1a. Analysis of RASSF1A binding partners by 
mass spectrometry identified the Hippo kinases MST1, MST2 and the oncogenic IkB 
kinase TBK1 as the most enriched RASSF1A-interacting proteins. The transcriptome of 
Rassf1a-/- livers was more deregulated than that of Sav1+/- livers, and the transcriptome 
of Rassf1a-/-, Sav1+/- livers was similar to that of Rassf1a-/- mice. We found that the 
levels of TBK1 protein were substantially upregulated in livers lacking Rassf1a. 
Furthermore, transcripts of several beta tubulin isoforms were increased in the Rassf1a-
deficient livers presumably reflecting a role of RASSF1A as a microtubule-stabilizing 
protein. In human liver cancer, RASSF1A frequently undergoes methylation at the 
promoter but this was not observed for MST1, MST2, or SAV1. Our results suggest a 
multifactorial role of RASSF1A in suppression of liver carcinogenesis. 
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Introduction: 
Liver cancer is one of the leading causes of cancer death worldwide. The Ras association 
domain family 1 (RASSF1) gene is located at chromosome 3p21.3 in a region frequently deleted 
in human solid tumors. The RASSF1 locus encodes two major transcripts referred to as 
RASSF1A and RASSF1C, which code for two proteins differing in their N-termini (1). The 
RASSF1A transcript and protein are frequently absent from human tumors due to methylation of 
the RASSF1A isoform-specific promoter (1,2). Methylation of the RASSF1A promoter often 
occurs at an early stage of tumor progression (3). Mice with Rassf1a gene deletion are prone to 
carcinogen-induced and spontaneous tumorigenesis (4-6).  
Although RASSF1A encodes a Ras association domain, this protein is effectively 
recruited to activated Ras only through heterodimerization with its closest homologue 
NORE1A/RASSF5 (7). RASSF1A is a potent microtubule binding and stabilizing protein (8,9). 
The non-catalytic protein RASSF1A is found in a complex with the kinases MST1 and MST2, 
the mammalian orhtologues of the tumor-suppressive Drosophila Hippo kinase and is 
associated with several other proteins of the Hippo pathway (10,11). RASSF1A inhibits the 
dephosphorylation of MST1/MST2 by phosphatases thus promoting an activated state of 
MST1/MST2 (12). The core components of the Hippo pathway are highly conserved across 
species. In mammals, the kinases MST1/MST2 can form a complex with another adaptor 
protein, SAV1, the mammalian counterpart of the Drosophila protein Salvador (13). MST1/MST2 
kinases activate two downstream kinases, LATS1 and LATS2 (14). The best-studied effector of 
the LATS kinases is YAP, an oncogenic transcriptional co-activator (15). Phosphorylated YAP is 
retained in the cytoplasm, which prevents it from activating transcription (16). In this model, the 
Hippo kinases are negative regulators of YAP. Hippo signaling is an important pathway for 
inhibition of cancer development in the mouse liver. Liver-specific deletion of Mst1 and Mst2 
combined, or deletion of Sav1 alone leads to liver enlargement and effective induction of 
hepatocellular carcinomas (HCC) or mixed liver tumors in mice [HCC/cholangiocarcinomas 
(CC)] (17-20).  
However, recent genome sequencing of human HCCs has failed to uncover mutations in 
components of the Hippo pathway (e.g. MST1/2, LATS1/2, SAV1) (21-23). Although 
amplification and/or overexpression of YAP as well as diminished YAP phosphorylation has 
been seen in a fraction of human liver cancers (19,24,25), the overall impact of this pathway on 
human cancer is still unclear.  
Our current report addresses the role of Rassf1a deletion on liver physiology and 
malignant transformation in the mouse. For comparison, we analyzed mice with single 
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homozygous deletion of Rassf1a or heterozygous deletion of Sav1, and also created a Sav1+/- 
Rassf1a-/- double knockout mouse model to study the function of these genes in liver 
tumorigenesis.  
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Materials and Methods: 
 
Generation of single and double Rassf1a and Sav1 gene knockout mice, tumor studies and liver 
tissue collection 
Rassf1a-/- mice were derived previously (4). We created Sav1 mutant mice by using standard 
gene targeting methods to delete exons 1 and 2 in 129S1 mouse embryonic stem cells. 
Homozygous Sav1 knockouts died in utero as reported previously (26). The Sav1 knockout 
colony was maintained in the heterozygous state. The Rassf1a and Sav1 mutant mice were 
crossed to Cre-Deleter/129 mice (27) to remove the neomycin selection cassette. Typical 
genotyping results are shown in Figure S1.  The Sav1 and Rassf1a mutant mice were 
maintained on the 129S1 background. Four mouse cohorts, Rassf1a+/+ Sav1+/+ (wildtype), 
Rassf1a-/- Sav1+/+, Rassf1a+/+ Sav1+/-, and Rassf1a-/- Sav1+/-, were established and monitored for 
spontaneous tumor formation, morbidity or death. Mice were euthanized when visibly moribund 
or whenever a growth/tumor became manifest, and a complete necroscopy was performed. 
Normal appearing liver or tumor tissues were fixed in 10% neutral-buffered formalin, and the 
remaining parts of liver tumor tissue and adjacent normal tissue were instantly frozen in liquid 
nitrogen and then stored at -80°C. The formalin fixed tissues were embedded in paraffin, and 
then stained with hematoxylin and eosin (H&E). 
 
Western blot and immunoprecipitation analysis 
Frozen tissue was ground in liquid nitrogen by using a pestle, and the total proteins were 
extracted with extraction buffer (50 mM HEPES, pH 7.4, 137 mM NaCl, 10% glycerol, 0.1% 
Triton-X 100, and 1x complete protease inhibitor cocktail (Roche)). Alternatively, soluble 
cytosolic fractions were prepared following a published procedure (28). Protein samples were 
resolved on 12% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Bio-
Rad). Nitrocellulose membranes were blocked with 5% nonfat milk (Bio-Rad) in PBST (PBS with 
0.1% Tween 20) and sequentially incubated with primary antibodies and HRP-conjugated 
secondary antibodies (Jackson ImmunoResearch Laboratories; West Grove, PA) in 5% nonfat 
milk in PBST. After incubation, blots were washed three times with PBST. We visualized the 
immunoreactive bands with Amersham ECL Prime Western Blotting Detection Reagent 
following the manufacturer’s instructions. Immunoprecipitation was performed as described 
previously (12). 
 
Combined bisulfite restriction analysis (COBRA) 
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Human liver cancer specimens and adjacent normal liver tissue were obtained from the City of 
Hope frozen tumor bank on an institutionally approved protocol. Tumor-free liver DNA from 
accident victims was obtained from Biochain. Genomic DNA was isolated from frozen tissue 
using the DNeasy Blood & Tissue Kit (Qiagen). One microgram of genomic DNA was treated 
with sodium bisulfite and the samples were subjected to ‘combined bisulfite restriction analysis’ 
(COBRA) (29) using primers as described previously (30). PCR products were digested with 
BstUI or TaqI restriction enzymes (New England Biolabs). These enzymes only cut initially 
methylated DNA after bisulfite conversion and PCR. The digested PCR products were 
separated by electrophoresis on 2% agarose gels.  
 
Antibodies 
Antibodies against phospho-IkB alpha (Ser32) (catalogue #2859), MST1 (#3682), YAP (#4912), 
phospho-YAP (Ser127) (#4911), TBK1 (#3013), NFkB1 (#13586), and phospho-p65 (Ser536) 
(#3033) were purchased from Cell Signaling Technologies. Antibodies against YAP1 (sc-
15407), TAZ (sc-48805), SAV1 (sc-135394), and NFkB/p65 (ac-109X) were purchased from 
Santa Cruz Biotechnology. Lamin B1 (ab16048), TUBB2A (#ab170931) and IkB alpha 
(ab32518) antibodies were obtained from Abcam. Anti- β-actin (A5441) and anti-FLAG (F7425) 
antibodies were from Sigma. Anti-MST2 (#1943-1) was from Epitomics, and anti-GAPDH 
(627408) was from Genetex. Anti-RASSF1A antibodies (M3-04 and M5-06) were raised against 
the N-terminal exon of RASSF1A (10).  
 
RNA isolation, microarray analysis and cDNA reverse transcription 
For total RNA isolation, we followed the instruction of the Ambion Purelink RNA mini kit. cDNA 
was synthesized from RNA template by using SuperScript III reverse transcriptase (Invitrogen). 
Real-time PCR amplifications were performed in 96-well optical reaction plates with SYBR 
Green by using Taq DNA polymerase (Qiagen). We used Affymetrix Gene 1.0-ST microarrays 
for gene expression analysis of mouse liver RNAs. Microarray data were analyzed using the 
Bioconductor package “ArrayTools”. Differentially expressed genes were selected by using a 
cutoff of P <= 0.005 and fold change >= 1.5. Heat maps were created by using Cluster v3.0 and 
visualized by Java Treeview. Raw data was deposited into the GEO database (accession 
number GSE73911). 
 
TCGA data analysis 
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DNA methylation data packages (Version 13) for the TCGA Liver Hepatocellular Carcinoma 
(LIHC) project were downloaded from the TCGA data portal on Dec 22, 2015. The R package 
Homo.sapiens was used to obtain the genomic locations of each gene, and GenomicRanges 
was used to get DNA methylation probes interrogating +/-1500 bp of the genomic range of the 
target gene. For each heatmap, the probes (rows) are arranged by their genomic location, and 
samples are clustered with hierarchical clustering to reveal patterns. Normalized isoform-level 
RNAseq data were downloaded from Firehose (http://gdac.broadinstitute.org). We used 
uc003dae for RASSF1A and uc003dab for RASSF1C expression levels, and for other genes 
only expressed isoforms were used. Corresponding Log2-transformed gene expression levels 
are plotted on top of each sample with a relative scale. 
 
 
Results: 
Tumor susceptibility of Rassf1a and Sav1 knockout mice 
Previous reports suggested that both RASSF1A and SAV1 form a complex through their C-
terminal SARAH domains with the Hippo kinases MST1 and MST2 (10,11). To study the 
contribution of these proteins to tumorigenesis, we generated mouse strains with germ line 
(whole body) deletion of Rassf1a (Rassf1a isoform-specific knockout by deletion of exon 1) 
and/or Sav1. Rassf1a homozygous gene knockout mice are viable and fertile (4,5), but, for the 
Sav1 gene knockout, only heterozygous mice could be obtained. This is due to embryonic 
lethality of complete Sav1 deletion in mice as also reported previously (26). Rassf1a-/- Sav1+/- 
mice were viable and fertile. Mouse colonies of four different genotypes, Rassf1a+/+ Sav1+/+, 
Rassf1a-/- Sav1+/+, Rassf1a+/+ Sav1+/-, and Rassf1a-/- Sav1+/-, were established on the 129S1 
genetic background and were observed for signs of tumor formation over extended periods of 
time. Overall survival was significantly different between wildtype and Rassf1a-/- Sav1+/- mice 
(P= 0.0063; log-rank test) and between Rassf1a-/- Sav1+/+ and Rassf1a-/- Sav1+/- mice (P<0.001) 
but not between wildtype and Rassf1a-/- Sav1+/+ (P=0.1016), wildtype and Rassf1a+/+ Sav1+/- 
(P=0.1144), or between Rassf1a+/+ Sav1+/- and Rassf1a-/- Sav1+/- (P=0.287) (Fig. 1). Curiously, 
some Rassf1a-/- Sav1+/+ mice survived to very old age.  
 Liver tumors developed in 19 of the 45 mice (42%) of the Rassf1a-/- Sav1+/+ genotype 
(Table 1). These varied from small, solitary nodules to large, multinodular masses that occupied 
entire lobes of the liver. The tumors were designated as hepatocellular adenomas (HA), 
hepatocellular carcinomas (HCC), mixed hepatocellular adenomas (mHA), or mixed 
hepatocellular carcinomas (mHCC) (Table 1).  Microscopic features of HA and HCC were 
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typical for these types of tumors (e.g., Fig. S2) and diagnoses were based upon standard 
histopathologic criteria (31).  Tumors designated as mHA or mHCC were morphologically 
distinct and did not clearly fit into any recognized classification of hepatocellular tumors. They 
are likely similar to tumors described in WW45+/- (same as Sav1+/-) mice and designated as 
“mixed-type” liver tumors thought to arise from hepatic progenitor (oval) cells (17). The mHA 
and mHCC had a component with obvious hepatocellular morphology and a significant second 
component of cells with small, oval to occasionally round or elongated nuclei and indistinct 
cytoplasm. These “small cells” formed solid sheets or irregular bands that penetrated into and 
sometimes surrounded nodules of neoplastic hepatocytes. The nuclei of the cells were 
occasionally arranged in rows or formed small, duct-like structures (Fig. 2). Because this second 
cellular component was uniformly small, highly homogeneous, and lacked mitotic figures, the 
designation of mHA or mHCC was based solely upon the morphology of the hepatocellular 
component of the tumor. In comparison to the Rassf1a-/- Sav1+/+ mice, only 6 of 30 (20%) 
wildtype mice had hepatocellular tumors (including one microscopic tumor) and these were all 
hepatocellular adenomas (Table 1) indicating increased tumor susceptibility and tumor 
progression in Rassf1a-deleted mice (P = 0.046; Chi square test). For the Sav1-targeted mice, 
47 out of 49 (96%) Rassf1a+/+ Sav1+/- mice were found with liver tumors at ages greater than 
one year. Similarly, 35 of 39 Rassf1a-/- Sav1+/- mice (90%) developed liver tumors suggesting 
that loss of one copy of Sav1 is a much more potent driver of liver tumor formation than loss of 
both copies of Rassf1a making it likely that loss of Sav1 is the dominant event in driving 
tumorigenesis in the double knockout mice (Table 1). Most of the livers from Sav1+/- mice 
showed signs of oval cell hyperplasia (Fig. 2E; Fig. S3). This change was only occasionally 
observed in Rassf1a-/- Sav1+/+ mice and was not seen in wild type mice. Oval cells are 
considered bipotential progenitors capable of differentiating into hepatocytes or cholangiocytes. 
However, distinct features of CC, e.g., clear gland formation, mucin production, and/or 
desmoplastic or fibrotic reaction, were not obvious in mice with a Sav1+/- or Rassf1a-/- genotype 
although most of the livers from Sav1+/- mice showed signs of oval cell expansion or bile duct 
hyperplasia (Fig. 2E,F). 
 
Analysis of the Hippo pathway 
Conditional biallelic deletion of the Sav1 gene in the mouse liver induces liver enlargement and 
liver tumor formation (17,18). Although in our work close to 100% of Rassf1a+/+ Sav1+/- mice or 
Rassf1a-/- Sav1+/- mice developed liver tumors after 12 months of age, we did not find any liver 
enlargement before tumors developed (Fig. S4). This finding suggests that one copy of Sav1 is 
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sufficient to prevent liver enlargement but is insufficient to prevent liver tumor formation. 
Complete loss of Rassf1a does not lead to liver enlargement either (Fig. S4). 
Since SAV1 and RASSF1A are components and potential regulators of the Hippo 
pathway, we analyzed levels of MST1 and MST2, YAP protein levels and phosphorylation on 
serine 127 of YAP in normal-appearing livers of mice of the different genotypes at the age of 6 
months (Fig. 3A). If the Hippo pathway is dysfunctional in gene-targeted mice, YAP protein 
should be less phosphorylated and total levels of YAP should increase owing to diminished 
degradation of YAP. First, we found that protein levels of both MST1 and MST2 were 
substantially reduced in the livers of Rassf1a+/+ Sav1+- mice. In Rassf1a-/- Sav1+/+ mice, MST1 
was decreased in only one of three mice and MST2 levels were similar to those in wildtype 
mice. In the double knockout mice, levels of MST1 were strongly decreased but MST2 
appeared at wildtype levels suggesting complex regulation of MST levels upon loss of their 
scaffold proteins (Fig. 3A).  
However, levels of YAP and phosphorylated YAP, their ratio, or levels of the YAP 
homologue TAZ did not differ noticeably in livers of all the genotypes (Fig. 3A). This suggested 
that although levels of MST1/2 were affected by deletion of SAV1, the standard readouts of the 
Hippo pathway, YAP and p-YAP, appeared largely unaltered in non-tumorous liver. Comparing 
liver tumors developing in Sav1+/- mice with adjacent normal liver tissue, we found much 
reduced levels of SAV1 protein in the majority of the tumors (Fig. 3B). Increased transcript level 
of the YAP target gene Ctgf is a marker of a dysfunctional Hippo pathway (32). We determined 
the gene expression levels of Ctgf in liver tumors developing in Rassf1a+/+ Sav1+/- mice. Thirteen 
of 14 liver tumor tissues expressed increased levels of Ctgf compared to the adjacent normal 
tissues (Fig. 3C). The high level of Ctgf expression in two tumors that retained SAV1 protein 
may be due to Hippo/YAP-independent mechanisms. We did not retain sufficient numbers of 
frozen tumors from Rassf1a-/- Sav1+/+ mice to compare Ctgf levels. The data suggests that the 
remaining Sav1 copy or perhaps other components of the pathway in the livers of Sav1+/- mice 
may eventually become disabled in founder cells giving rise to a dysfunctional Hippo pathway 
and producing liver tumors. However, the overall protein expression levels of YAP and 
phosphorylated YAP are not noticeably altered in bulk liver tissue of Sav1 heterozygous or 
Rassf1a homozygous mutant mice (Fig. 3A).  
 
TBK1, a new RASSF1A-interacting protein 
To identify potentially novel RASSF1A-interacting proteins, we performed immunoprecipitation 
of endogenous RASSF1A from HeLa cells. Co-precipitating proteins were identified by mass 
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spectrometry (Fig. 4A). The most significantly enriched proteins were three kinases, MST1, 
MST2 and TBK1 (Tank binding kinase 1). Figure 4B shows co-immunoprecipitation of 
endogenous RASSF1A and TBK1. TBK1 is an oncogenic noncanonical IkB kinase, which 
phosphorylates IkB to release NFkB, which can induce the transcription of various pro-
inflammatory and anti-apoptotic genes (33,34). We then analyzed protein expression levels of 
TBK1 in Rassf1a-/- Sav1+/+ mouse liver tissues and found that TBK1 protein expression was 
consistently and substantially increased in all Rassf1a knockout livers compared with the wild 
type livers at the same age (18 months) (Fig. 4C). A similar increase of TBK1 levels was 
consistently found at earlier and later ages of the mice and also was seen in Rassf1a-/- Sav1+/- 
double knockout mice but not in Rassf1a+/+ Sav1+/- mice (data not shown).  
The best-studied functions of TBK1 are through regulating the classical NFkB pathway 
via p65 phosphorylation. Therefore, we determined the total protein expression of p65, its 
phosphorylated form p-p65 and its binding partner, NFkB1/p50 which complexes with p65 and 
IkBα in the cytoplasm. p65 or p-p65 did not show a notable increase in Rassf1a-/- Sav1+/+ mice. 
Also, p105 and its truncated form p50 did not consistently show higher protein levels upon 
Rassf1a deletion (Fig. 4C). 
 
The liver transcriptomes of Sav1 and Rassf1a knockout mice 
We isolated RNA from livers of the four mouse genotypes at one year of age processing four 
biological replicates for each genotype. The RNA was analyzed on Affymetrix 1.0-ST 
microarrays. The four genotypes could be well separated by heat maps (Fig. 5A). Using a P-
value cutoff of P<0.005, we found a relatively small number of up- or downregulated genes in 
Rassf1a+/+ Sav1+/- mice relative to wildtype mice (Fig. 5B; Supplementary Tables S1 and S2). As 
expected, levels of Sav1 transcripts were reduced to about 50%. However, at the same 
significance level, the transcriptomes of Rassf1a-/- Sav1+/+ and Rassf1a-/- Sav1+/- mice were 
more substantially altered in comparison to those of Rassf1a+/+ Sav1+/- mice (Fig. 5B; Tables S1 
and S2). There was some overlap between the genotypes. Most notably, expression differences 
in both directions of Rassf1a-/- Sav1+/+ and Rassf1a-/- Sav1+/- mice relative to wildtype were more 
similar to each other than to Rassf1a+/+ Sav1+/- mice (Fig. 5B; Table S2).  
Gene ontology analysis did not provide any enrichment for specific gene or functional 
categories in the Rassf1a+/+ Sav1+/- mice. In contrast, the same analysis for the Rassf1a-deleted 
genotypes uncovered enrichment of two major functional categories: the circadian clock and 
microtubule polymerization (Fig. S5). This analysis did not reveal a gene category related to the 
NFkB pathway or to inflammatory responses in Rassf1a-/- genotype livers that could perhaps be 
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traced back to increased levels of TBK1. Interestingly, however, we found that several beta 
tubulin genes, including Tubb1, Tubb2a, Tubb2b and Tubb5 were among the top 60 
upregulated genes in Rassf1a knockout livers (Supplementary Table S1). These beta tubulin 
genes were significantly upregulated (up to 4-fold) in Rassf1a-/- Sav1+/+ and Rassf1a-/- Sav1+/- 
mice but not in Rassf1a+/+ Sav1+/- livers (Fig. 5C and Table S1). In fact, most beta tubulin genes 
were upregulated except for Tubb3 and Tubb4a, which are beta tubulin isoforms preferentially 
expressed in the nervous system. Genes coding for alpha and gamma tubulin proteins were not 
significantly different in the knockouts. At the protein level, TUBB2A was increased only slightly 
in livers of Rassf1a knockout mice (Fig. 5C). 
The enrichment of circadian factors in Rassf1a-deleted livers (Fig. S5) was unexpected. 
One differentially expressed gene was Usp2. The ubiquitin-specific protease USP2 is a key 
driver of the circadian clock (35). Interestingly, USP2 is also a binding partner and negative 
regulator of the Rassf1a interacting kinase, TBK1 (36). Although Tbk1 itself was not 
transcriptionally misregulated in Rassf1a knockout mice, we observed that at the transcript 
level, factors regulating TBK1 protein stability, including Usp2 and Dtx4, were dysregulated. 
Usp2 was the second most significantly altered gene in Rassf1a-/- Sav1+/+ livers (downregulated 
~16-fold; Table S1). Dtx4, the sixth most significantly altered (upregulated) gene (Table S1) in 
this genotype is an E3 ubiquitin ligase and key suppressor of TBK1 targeting this kinase for 
degradation (37). The data suggest that a regulatory feedback loop may exist between 
RASSF1A, TBK1 and its modifiers DTX4 and USP2. 
 
Human liver cancers show frequent methylation of the RASSF1A promoter, but minimal 
methylation of other Hippo pathway genes 
Promoter hypermethylation of tumor suppressor genes is a potential contributor to tumor 
formation. Since mutations in genes of the Hippo pathway are uncommon in human cancers 
(16) including liver cancer, we analyzed several genes of the pathway for methylation at their 
promoters in 22 pairs of human normal tissue and tumor tissue of the liver (Fig. S6, S7; Table 
S3). Liver cancer patients often have predisposing conditions including cirrhosis, HBV, or HCV 
(Table S3). We analyzed promoter methylation of the target genes by using combined bisulfite 
restriction analysis (COBRA) on normal tissues and tumor tissues (Fig. S6, S7). Seventeen out 
of 22 (77%) of the liver cancer patients had higher RASSF1A methylation in the tumor tissues 
compared with the adjacent normal tissues (Fig. S6A). Partial methylation of RASSF1A was 
seen in some tumor-adjacent livers and in liver DNA from an 83-year old tumor-free liver. Our 
RASSF1A promoter methylation data are consistent with other groups’ earlier findings showing 
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extensive methylation of RASSF1A in HCC (38-40). However, we detected no methylation at 
the SAV1 promoter (Fig. S6B). Furthermore, we found no methylation in human liver tumors at 
the promoters of the genes MST1 and MST2 (Fig. S7).  
 To support this analysis, we analyzed HCC DNA methylation data from TCGA (Fig. 6). 
This analysis shows methylation of the RASSF1A but not the RASSF1C or SAV1 promoters in 
HCC in the TCGA data set. The more highly methylated tumors (indicated by a dotted line in 
Fig. 6A) had the lowest expression of RASSF1A. Although the TCGA sample number for normal 
liver is still limited, there seems to be a trend for lower expression of SAV1 in some HCCs. 
However, about half of the HCCs still express high levels of SAV1 (Fig. 6B). Analysis of TCGA 
data for MST1 and MST2 also show a lack of methylation at their promoter-associated CpG 
islands (Fig. S8). MST1 is expressed at rather high levels and is downregulated in very few 
HCCs. Unexpectedly, MST2 is upregulated in about half the HCCs relative to normal liver 
tissues (Fig. S8B). This data suggests that the RASSF1A gene is frequently and extensively 
methylated and silenced in human liver tumors but that SAV1 or MST1/2 are less commonly 
affected.  
 
Discussion: 
In this study, we created three mouse models in which scaffold protein binding partners of the 
mammalian Hippo kinases MST1 and MST2 were deleted. Liver-specific deletion of Mst1 and 
Mst2 together (18-20), as well as liver-specific homozygous deletion of Sav1 (17,18), produced 
hepatomegaly and effectively induced hepatocellular carcinomas in mice. These deletions 
increase the pool of hepatic progenitor cells (oval cells), a phenomenon we also observed in our 
Sav1+/- mice and to a lesser extent in Rassf1a-/- mice. Sav1+/- mice also developed liver cancer 
in a previous study (17). It remains unknown why constitutive deletion of Sav1 in the mouse has 
such a prominent effect on liver tumor formation and rarely affects other tissues even though 
YAP, its best-studied downstream effector, plays a general role in many cell types.  
 In our comparative mouse studies, we determined that homozygous deletion of Rassf1a 
causes liver tumor susceptibility. In previous studies, liver tumors were not observed as a 
common type of tumor in Rassf1a-/- mice (4,5). These mice were on a different genetic 
background (129SvJ x C57BL/6). The heterozygous deletion of Sav1 was much more potent in 
promoting liver cancer (Table 1) even though both RASSF1A and SAV1 are binding partners 
and activators of the MST kinases (10,14,41). Although we are unable to offer a definitive 
explanation for these differences in tumor susceptibility between the Sav1 and Rassf1a deleted 
genotypes at this time, one likely possibility is the redundancy of the RASSF protein family. 
on March 21, 2016. © 2016 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 15, 2016; DOI: 10.1158/0008-5472.CAN-15-3010 
  
  
13
While there is only one SAV1-like protein in mammalian genomes, there are 10 RASSF proteins 
defined by the presence of a RAS association domain (42). Six of these proteins (RASSF1-6) 
have a C-terminal RAS association domain. The proteins most closely related to RASSF1 are 
RASSF3 and RASSF5 (a.k.a. NORE1). We found that the Rassf5 gene was upregulated 1.24-
fold in the liver of Rassf1a knockout mice (Table S1) but other Rassf genes were not changed. 
Deletion of multiple members of the C-terminal Rassf family may be necessary to elicit a more 
dramatic phenotype in animal models.  
 Mice with heterozygous deletion of Sav1 or homozygous deletion of Rassf1a did not 
show any signs of liver enlargement prior to development of tumors in contrast to mice with 
conditional ablation of Sav1 or Mst1 and Mst2 in the liver (17-20) or liver-specific 
overexpression of Yap (43). This data suggests that the core Hippo pathway restraining tissue 
overgrowth by inhibiting YAP activity in the liver is functional in the absence of Rassf1a or in 
presence of only one copy of Sav1. However, these deletions led to the formation of liver 
tumors. It is likely that the remaining functional copy of Sav1 is lost or disabled in tumor-initiating 
cells of Sav1+/- livers. The downstream consequences are activation of YAP-dependent 
expression of pro-growth genes as exemplified by increased expression of Ctgf (Fig. 3C). The 
phenotype of Rassf1a homozygous deletion is milder than that of Sav1 single copy deletion but 
is still pronounced. It can be hypothesized that loss of Rassf1a cooperates with other tumor-
driving events in liver cancer formation as previously demonstrated for hematological 
malignancies (6). 
 Besides its involvement in the Hippo pathway, RASSF1A has additional functions that 
when impaired may contribute to malignant transformation. As an established microtubule 
binding and stabilizing protein (8), loss of RASSF1A may interfere with events such as cell 
migration (44) and mitosis (8,10,45,46). Defects in cell migration or mitosis are likely 
contributors to oncogenesis. Interestingly, we observed that loss of Rassf1a leads to increased 
expression of a number of beta tubulin isoform-encoding genes including Tubb1, Tubb2a, 
Tubb2b and Tubb5. This finding suggests that loss of microtubule stabilization by RASSF1A 
may invoke compensatory events by increasing transcription of beta tubulin genes. However, 
this compensation may be insufficient contributing to the tumor-promoting phenotype of Rassf1a 
loss. 
 We identified the kinase TBK1 as a strong RASSF1A-interacting protein (Fig. 4). This 
interaction was further proven to be relevant in vivo by the clearly enhanced levels of TBK1 
protein in every liver sample obtained from mice with Rassf1a deletion. The absence of a 
protein commonly leads to diminished levels of its binding partner(s) owing to reduced protein 
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stability in absence of the partner. However, this is not the case with TBK1, which showed 
increased levels upon deletion of Rassf1a. One possible explanation is that RASSF1A promotes 
degradation of TBK1 upon binding, a scenario, which requires additional investigation. In any 
event, the data suggest that RASSF1A is a negative regulator of the oncogenic kinase TBK1 
because in the absence of RASSF1A, the levels of this kinase are increased. TBK1 is best 
known as an activator of the NFkB pathway and has oncogenic properties (33,34). Deletion of 
Rassf1a did not lead to a noticeable activation of the pathway and of NFkB target genes in the 
liver (Fig. 4; Table S1). We also did not observe an increase of inflammatory cells in sections of 
livers from Rassf1a-/- mice. For these reasons, NFkB pathway-independent functions of TBK1 
may be important for tumor promotion in the liver and these may be increased upon loss of 
Rassf1a. Mouse models have shown that TBK1 is critical in protecting the liver from apoptosis 
(47). TBK1 can directly activate AKT by phosphorylating the activation loop (48). Furthermore, it 
has been shown that TBK1 is a mitotic kinase that phosphorylates and activates Polo-like 
kinase 1 (PLK1) (49). Interference with mitotic progression is generally a potential tumor-
promoting event. Importantly, a role of RASSF1A and the Hippo pathway in mitotic exit and 
prevention of polyploidy has been proposed previously (10), suggesting that loss of RASSF1A 
may have a multipronged effect on correct execution of mitosis, which may explain aspects of 
the tumor-predisposing phenotype of Rassf1a loss.  
   Lastly, our studies add information to the possible role of the Hippo pathway in human 
liver cancer. Several mouse models with deletions of core components of the pathway clearly 
suggest that failure of Hippo signaling promotes liver cancer (50). However, mutations of SAV1, 
RASSF1A, MST1, MST2, or LATS1, LATS2 are extremely rare in human cancer (16). Although 
upstream Hippo signaling regulators such as FAT1, FAT4, or NF2 may be mutated in certain 
types of malignancies, they are not commonly mutated in human liver cancer either. Therefore, 
one may consider epigenetic inactivation of Hippo pathway tumor suppressor genes as a 
potential tumor-driving event. However, our own studies (Fig. S6, S7) along with previous data 
(38-40) and data obtained from TCGA (Fig. 6; Fig. S8) suggest that the only Hippo pathway 
gene commonly silenced by epigenetic processes in HCC is RASSF1A. This is particularly 
puzzling inasmuch as epigenetic inactivation of SAV1 would be expected to be a much more 
efficient tumor-promoting event than silencing of RASSF1A, given the data from our mouse 
models. Although SAV1 seems to be downregulated in a subset of HCCs, MST2 is 
overexpressed rather than downregulated in many of the TCGA samples. Furthermore, 
although Sav1 mutant livers are characterized by an expansion of the oval cell pool, recent data 
has cast doubt onto whether these progenitor cells can be considered general precursors of 
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HCC in various liver cancer models, as opposed to mature hepatocytes which may undergo 
dedifferentiation (51). Future studies are needed to resolve the complex roles of the Hippo 
pathway in human HCC.  
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Table 1: Liver tumor formation in Rassf1a and Sav1 deficient mice 
 
Rassf1a Sav1 
No. of 
Mice 
Mean Age 
(days) 
Median 
Age 
(days) 
No of mice 
with 
hepatocellular 
tumors 
Hepato-
cellular 
CA 
Hepato-
cellular 
CA, 
mixed* 
Hepato-
blastoma 
Hepato-
cellular 
adenoma 
Hepato-
cellular 
adenoma, 
mixed* 
wt +/- 49 591 607 47 35 14 32 17 
          95.90% 71.40% 28.60% 0% 65.30% 34.70% 
-/- +/- 39 583 626 35 30 9 1 31 15 
          89.70% 77% 23.10% 2.60% 79.50% 38.50% 
-/- wt 45 643 642 19 4 1 0 14 2 
          42% 8.90% 2.20% 0% 31.10% 4.40% 
wt wt 30 613 659 6 0 0 0 6 0 
          20% 0% 0% 0% 20% 0% 
 
 
* The designation mixed tumor refers to tumors which in addition to a hepatocellular component also had a "small cell / oval cell" 
component. Mean age and median age refer to overall survival of all mice of the respective genotype.  
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Figure Legends: 
 
Figure 1: 
Survival of Rassf1a and Sav1 knockout mice. 
Overall survival is plotted for Rassf1a+/+ Sav1+/+, Rassf1a-/- Sav1+/+, Rassf1a+/+ Sav1+/-, and 
Rassf1a-/- Sav1+/- mice. 
 
 
Figure 2: 
Characterization of liver tumors. 
A-D. Liver tumor from a Sav1+/+ Rassf1a-/- mouse. Low magnification photomicrograph 
demonstrating multinodular “mixed” type tumor (panel A). Areas with obvious hepatocellular 
morphology (h) are intermixed with areas having “small cell” morphology (*). This is shown at 
slightly higher magnification in panel B. At still higher magnification (panels C and D), the “small 
cell” component (*) of the mixed tumors is found to be composed of cells that have oval to 
occasionally round or elongated nuclei (panel C; arrows) and vary from having no organization 
(panel C) to well-defined (panel D) orientation into rows or duct-like structures (panels D; 
arrowheads). Areas of obvious hepatocellular morphology are labeled (h) in panels C and D. 
H&E staining. E. Percentage of mice with oval cell hyperplasia of the liver. 
F. Percentage of mice with bile duct hyperplasia. 
 
 
Figure 3: 
Analysis of Hippo pathway components. 
A. Western blot of Hippo pathway components in liver lysates of 6-month old mice of the 
different genotypes. Each lane represents a sample from an individual mouse. 
B. Reduction of SAV1 protein levels in liver tumors developing in Rassf1a+/+ Sav1+/- mice. 
C. Expression differences of the YAP target gene Ctgf between liver tumors developing in 
Rassf1a+/+ Sav1+/- mice and adjacent normal liver in the same mice. The expression data were 
normalized relative to Gapdh expression. All tumors were HCC except tumors 3852, 3872, 3939 
and 3979, which were adenomas. 
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Figure 4: 
RASSF1A binds to and regulates the levels of the oncogenic kinase TBK1. 
A. Immunoprecipitation of RASSF1A-interacting proteins from HeLa cells. Endogenous 
RASSF1A was immunoprecipitated with two anti-RASSF1A antibodies, M3-04 and M5-06. 
Prominent bands on Coomassie blue stained gels were excised and proteins indicated by 
arrows were identified by mass spectrometry.  
B. Proteins from HeLa cells were immunoprecipitated with anti-RASSF1A, anti-TBK1 antibodies 
or control IgG (IP). After separation on SDS gels, Western blots (WB) were conducted with the 
indicated antibodies. The asterisks indicate IgG bands. 
C. Soluble cytosolic liver protein extracts from mice of different genotypes at 18 months of age 
were analyzed by Western blot for levels of TBK1 and proteins of the NFkB pathway. Each lane 
represents a sample from an individual mouse. 
 
 
Figure 5: 
Gene expression differences in livers from mice with Rassf1a and/or Sav1 deletion.  
A. Heat map showing differentially expressed genes in livers of 12-month old mice with 
genotypes Rassf1a+/+ Sav1+/+ (WT), Rassf1a+/+ Sav1+/- (SA), Rassf1a-/- Sav1+/+ (RA) and 
Rassf1a-/- Sav1+/- (RA_SA). Samples with the same genotype cluster together. 
B. Venn diagram showing differentially expressed genes (P<=0.005), up- or downregulated, in 
the livers of the three knockout genotypes versus wildtype liver.  
C. Differences in expression levels for the beta tubulin genes Tubb1, Tubb2a, Tubb2b and 
Tubb5 as determined from the microarray data. Levels of TUBB2A protein in wildtype and 
Rassf1a-/- Sav1+/+ mouse livers were assessed by Western blot using beta-actin as a control. 
Each lane represents a sample from an individual mouse. 
 
 
 
Figure 6: 
Methylation and expression of RASSF1A and SAV1 in human HCC. 
A. Data for the RASSF1 locus were extracted from TCGA data portal 
(http://cancergenome.nih.gov/). Expression (RNA-seq) and DNA methylation (Illumina 450k 
array) data were displayed for individual specimens (each column). The methylation data are 
plotted for individual CpG sites along the locus (each row). The dotted bar above the 
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methylation data indicates groups of HCC specimens with higher level of DNA methylation at 
the RASSF1A CpG island that also show lack of gene expression (green). White bars show 
samples lacking expression data. B. TCGA data for the SAV1 locus. 
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Rassf1a Sav1 
No. of 
Mice 
Mean Age 
(days) 
Median 
Age 
(days) 
No of mice 
with 
hepatocellular 
tumors 
Hepato-
cellular 
CA 
Hepato-
cellular 
CA, 
mixed* 
Hepato-
blastoma 
Hepato-
cellular 
adenoma 
Hepato-
cellular 
adenoma, 
mixed* 
wt +/- 49 591 607 47 35 14 
 
32 17 
          95.90% 71.40% 28.60% 0% 65.30% 34.70% 
-/- +/- 39 583 626 35 30 9 1 31 15 
          89.70% 77% 23.10% 2.60% 79.50% 38.50% 
-/- wt 45 643 642 19 4 1 0 14 2 
          42% 8.90% 2.20% 0% 31.10% 4.40% 
wt wt 30 613 659 6 0 0 0 6 0 
          20% 0% 0% 0% 20% 0% 
 
 
* The designation mixed tumor refers to tumors which in addition to a hepatocellular component also had a "small cell / oval cell" 
component. Mean age and median age refer to overall survival of all mice of the respective genotype.  
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